Pravin U. Dugel, MD
Anti-VEGF monotherapy will go down in medical history as a treatment model that was both insurmountable and unsustainable.
It was insurmountable because of the historic gains that were seen in a disease, neovascular macular degeneration, that had miserable treatment results earlier. We went from essentially not being able to treat our patients at all and watching them go blind to being able to maintain vision in 90% of our patients with exudative macular degeneration. We were able to actually improve vision in 30% to 40% of our patients with neovascular macular degeneration with anti-VEGF monotherapy.